Khondrion Presents Phase II KHENERGY Trial Data
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY…
CRF Health’s TrialMax Touch® Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study
CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has been…